Parmax Pharma Stock Plummets to New 52-Week Low at Rs. 30.35

Parmax Pharma has reached a significant milestone today, hitting a 52-week low of Rs. 30.35. This decline marks a notable downturn for the microcap pharmaceutical company, which has been under pressure, experiencing a consecutive fall over the last four days and a total decline of 10.55% during this period.
Today's performance saw Parmax Pharma underperforming its sector by 4.75%, reflecting broader challenges within the market. The stock's intraday low of Rs. 30.35 represents a decrease of 3.56% from the previous close. Additionally, Parmax Pharma is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a sustained downward trend.

Over the past year, the stock has generated a return of -31.49%, contrasting sharply with the Sensex's performance of -4.05%. The company's financial metrics reveal a negative book value and weak long-term growth, with net sales declining by 43.96% in the latest six months. As Parmax Pharma navigates these challenges, its market position remains under scrutiny.